OS Therapies Incorporated (OSTX) Noticias

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form DEF 14A - Other definitive proxy statements

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate...

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer...

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2

Patent Term Adjustment will provide market exclusivity in the United States into 2040 for all therapeutic indications OS Therapies, Inc...

Form 4 - Statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities